5.43
Schlusskurs vom Vortag:
$5.40
Offen:
$5.4
24-Stunden-Volumen:
738.43K
Relative Volume:
0.62
Marktkapitalisierung:
$1.22B
Einnahmen:
$596.48M
Nettoeinkommen (Verlust:
$123.72M
KGV:
9.9015
EPS:
0.5484
Netto-Cashflow:
$106.59M
1W Leistung:
+0.37%
1M Leistung:
-0.18%
6M Leistung:
+37.12%
1J Leistung:
+43.27%
Curevac N V Stock (CVAC) Company Profile
Vergleichen Sie CVAC mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CVAC
Curevac N V
|
5.43 | 1.22B | 596.48M | 123.72M | 106.59M | 0.5484 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-13 | Herabstufung | Jefferies | Buy → Hold |
2024-04-25 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2023-06-08 | Eingeleitet | SVB Securities | Outperform |
2023-01-19 | Hochstufung | UBS | Neutral → Buy |
2023-01-09 | Hochstufung | Jefferies | Hold → Buy |
2022-01-21 | Herabstufung | BofA Securities | Neutral → Underperform |
2022-01-18 | Eingeleitet | JMP Securities | Mkt Outperform |
2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
2021-06-17 | Herabstufung | BofA Securities | Buy → Neutral |
2021-04-26 | Fortgesetzt | Credit Suisse | Underperform |
2021-04-26 | Eingeleitet | Guggenheim | Neutral |
2020-12-10 | Herabstufung | Credit Suisse | Neutral → Underperform |
2020-09-08 | Eingeleitet | BofA Securities | Buy |
2020-09-08 | Eingeleitet | Credit Suisse | Neutral |
2020-09-08 | Eingeleitet | Jefferies | Hold |
Alle ansehen
Curevac N V Aktie (CVAC) Neueste Nachrichten
CureVac N.V.Finanzen.net - Finanzen.net
What analysts say about CureVac N.V. stockFree Consultation - jammulinksnews.com
CureVac N.V. Stock Analysis and ForecastUnmatched profit potential - jammulinksnews.com
What drives CureVac N.V. stock priceSky-high return potential - jammulinksnews.com
Is CureVac N.V. a good long term investmentExceptional stock performance - Autocar Professional
CureVac: Pipeline pruning’s nasty effect - MarketScreener
CureVac N.V. (CVAC) Has Gained Over 16% In One Month. Here Is Why - Insider Monkey
Tesla chief Elon Musk teams up with Covid-19 player CureVac to build ‘RNA microfactories’ - Endpoints News
CureVac Announces Key Resolutions from Annual Shareholders Meeting - TipRanks
CureVac (CVAC) Downgraded by UBS as Acquisition Looms | CVAC Stock News - GuruFocus
CureVac stock downgraded to neutral by UBS after BioNTech acquisition - Investing.com UK
CureVac Announces Key Appointments and Auditor Reappointment at Annual Meeting - TipRanks
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Zacks Investment Research
Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive - Investing.com
BioNTech SE Announces Acquisition of CureVac N.V. - TipRanks
Germany: BioNTech to acquire CureVac in all-stock transaction - Investors in Healthcare
BioNTech to Acquire CureVac in Strategic Move - TipRanks
CureVac agrees to pay Biontech termination fee Of $43.8 mln under specified circumstances - MarketScreener
5 Stocks To Ride The German Market RallyCureVac (NASDAQ:CVAC), BioNTech (NASDAQ:BNTX) - Benzinga
BioNTech to Acquire CureVac in US$1.25 Billion All-Stock Transaction - Global Legal Chronicle
There's No Escaping CureVac N.V.'s (NASDAQ:CVAC) Muted Revenues Despite A 50% Share Price Rise - simplywall.st
CureVac’s SWOT analysis: mRNA pioneer’s stock faces pivotal year ahead By Investing.com - Investing.com Nigeria
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of - Bluefield Daily Telegraph
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BioNTech CureVac Acquisition Boosts Cancer Drug Pipeline - Industry Leaders Magazine
CureVac (CVAC) Receives Downgrade and Price Target Reduction fro - GuruFocus
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer - GlobeNewswire
Jefferies cuts CureVac stock rating to hold on BioNTech acquisition By Investing.com - Investing.com UK
BioNTech: Oddo BHF raises target price - marketscreener.com
BioNTech to buy CureVac in USD 1.25 billion all-stock deal - Medical Dialogues
CureVac Stock: BioNTech's Billion-Dollar Takeover Bid - sharewise
BioNTech (BNTX) to Acquire CureVac in $1.25 Billion All-Stock De - GuruFocus
CureVac (CVAC) Downgraded by Jefferies Analyst After BioNTech Acquisition Agreement | CVAC Stock News - GuruFocus
BioNTech Announces Strategic Transaction to Acquire CureVac in P - GuruFocus
BioNTech Announces Strategic Acquisition of CureVac - TipRanks
Biontech’s $1.25B Curevac buyout removes mRNA lawsuit uncertainty - BioWorld MedTech
BioNTech to Acquire CureVac in $1.25B Deal - USA Herald
BioNTech's Acquisition Of CureVac Brings Complementary Method To Target Cancer (BNTX) - Seeking Alpha
5 Firms Guide $1.25B BioNTech, CureVac Oncology Deal - Law360
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, SOAR, MTWO on Behalf of Shareholders - MarketScreener
BioNTech to acquire CureVac in $1.25 billion all-stock deal By Investing.com - Investing.com South Africa
Finanzdaten der Curevac N V-Aktie (CVAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):